-
Je něco špatně v tomto záznamu ?
Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic
K. Agrawal, V. Das, P. Vyas, M. Hajdúch,
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
Grantová podpora
NV15-31984A
MZ0
CEP - Centrální evidence projektů
- MeSH
- antitumorózní látky farmakologie terapeutické užití MeSH
- azacytidin analogy a deriváty farmakologie MeSH
- chemorezistence MeSH
- DNA-(cytosin-5)-methyltransferasa 1 antagonisté a inhibitory MeSH
- lidé MeSH
- metylace DNA účinky léků MeSH
- nukleosidy farmakologie MeSH
- objevování léků * MeSH
- thioguanin farmakologie MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
DNA methylation plays a pivotal role in the etiology of cancer by mediating epigenetic silencing of cancer-related genes. Since the relationship between aberrant DNA methylation and cancer has been understood, there has been an explosion of research at developing anti-cancer therapies that work by inhibiting DNA methylation. From the discovery of first DNA hypomethylating drugs in the 1980s to recently discovered second generation pro-drugs, exceedingly large number of studies have been published that describe the DNA hypomethylation-based anti-neoplastic action of these drugs in various stages of the pre-clinical investigation and advanced stages of clinical development. This review is a comprehensive report of the literature published in past 40 years, on so far discovered nucleosidic DNA methylation inhibitors in chronological order. The review will provide a complete insight to the readers about the mechanisms of action, efficacy to demethylate and re-express various cancer-related genes, anti-tumor activity, cytotoxicity profile, stability, and bioavailability of these drugs. The review further presents the far known mechanisms of primary and secondary resistance to azanucleoside drugs. Finally, the review highlights the ubiquitous role of DNA hypomethylating epi-drugs as chemosensitizers and/or priming agents, and recapitulate the combinatorial cancer preventive effects of these drugs with other epigenetic agents, conventional chemo-drugs, or immunotherapies. This comprehensive review analyzes the beneficial characteristics and drawbacks of nucleosidic DNA methylation inhibitors, which will assist the pre-clinical and clinical researchers in the design of future experiments to improve the therapeutic efficacy of these drugs and circumvent the challenges in the path of successful epigenetic therapy.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012827
- 003
- CZ-PrNML
- 005
- 20190416122045.0
- 007
- ta
- 008
- 190405s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pharmthera.2018.02.006 $2 doi
- 035 __
- $a (PubMed)29454856
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Agrawal, Khushboo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hněvotínská 5, 77900 Olomouc, Czech Republic; Cancer Research Czech Republic, Hněvotínská 5, 77900 Olomouc, Czech Republic.
- 245 10
- $a Nucleosidic DNA demethylating epigenetic drugs - A comprehensive review from discovery to clinic / $c K. Agrawal, V. Das, P. Vyas, M. Hajdúch,
- 520 9_
- $a DNA methylation plays a pivotal role in the etiology of cancer by mediating epigenetic silencing of cancer-related genes. Since the relationship between aberrant DNA methylation and cancer has been understood, there has been an explosion of research at developing anti-cancer therapies that work by inhibiting DNA methylation. From the discovery of first DNA hypomethylating drugs in the 1980s to recently discovered second generation pro-drugs, exceedingly large number of studies have been published that describe the DNA hypomethylation-based anti-neoplastic action of these drugs in various stages of the pre-clinical investigation and advanced stages of clinical development. This review is a comprehensive report of the literature published in past 40 years, on so far discovered nucleosidic DNA methylation inhibitors in chronological order. The review will provide a complete insight to the readers about the mechanisms of action, efficacy to demethylate and re-express various cancer-related genes, anti-tumor activity, cytotoxicity profile, stability, and bioavailability of these drugs. The review further presents the far known mechanisms of primary and secondary resistance to azanucleoside drugs. Finally, the review highlights the ubiquitous role of DNA hypomethylating epi-drugs as chemosensitizers and/or priming agents, and recapitulate the combinatorial cancer preventive effects of these drugs with other epigenetic agents, conventional chemo-drugs, or immunotherapies. This comprehensive review analyzes the beneficial characteristics and drawbacks of nucleosidic DNA methylation inhibitors, which will assist the pre-clinical and clinical researchers in the design of future experiments to improve the therapeutic efficacy of these drugs and circumvent the challenges in the path of successful epigenetic therapy.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a antitumorózní látky $x farmakologie $x terapeutické užití $7 D000970
- 650 _2
- $a azacytidin $x analogy a deriváty $x farmakologie $7 D001374
- 650 _2
- $a DNA-(cytosin-5)-methyltransferasa 1 $x antagonisté a inhibitory $7 D000076123
- 650 _2
- $a metylace DNA $x účinky léků $7 D019175
- 650 12
- $a objevování léků $7 D055808
- 650 _2
- $a chemorezistence $7 D019008
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nukleosidy $x farmakologie $7 D009705
- 650 _2
- $a thioguanin $x farmakologie $7 D013866
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Das, Viswanath $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hněvotínská 5, 77900 Olomouc, Czech Republic; Cancer Research Czech Republic, Hněvotínská 5, 77900 Olomouc, Czech Republic.
- 700 1_
- $a Vyas, Pankhuri $u Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, 21205 Baltimore, MD, United States.
- 700 1_
- $a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hněvotínská 5, 77900 Olomouc, Czech Republic; Cancer Research Czech Republic, Hněvotínská 5, 77900 Olomouc, Czech Republic. Electronic address: marian.hajduch@upol.cz.
- 773 0_
- $w MED00006662 $t Pharmacology & therapeutics $x 1879-016X $g Roč. 188, č. - (2018), s. 45-79
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29454856 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190416122111 $b ABA008
- 999 __
- $a ok $b bmc $g 1392137 $s 1051132
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 188 $c - $d 45-79 $e 20180215 $i 1879-016X $m Pharmacology & therapeutics $n Pharmacol Ther $x MED00006662
- GRA __
- $a NV15-31984A $p MZ0
- LZP __
- $a Pubmed-20190405
